New Combination Approach Targets Both Immune Attack and Beta-Cell Recovery in Type 1 Diabetes

Type 1 diabetes develops when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Once destroyed, these cells can no longer make insulin, forcing people to inject it for life. Current insulin therapy is lifesaving but doesn't stop the autoimmune attack or restore the body's ability to produce its own insulin.

This gap has driven researchers to explore disease-modifying approaches—treatments that could address the root cause rather than just replacing the missing hormone.

Researchers designed a two-part treatment combining omeprazole, a proton-pump inhibitor commonly used to treat acid reflux, with an antibody fragment called anti-CD3 F(ab')₂. The theory was that these drugs might work together to calm the autoimmune attack while simultaneously encouraging new beta cells to grow.

The team tested this combination in two mouse models of Type 1 diabetes: one using an accelerated disease protocol and another with naturally occurring diabetes. Both are widely used to mimic how the disease develops in humans.

Mice receiving the combination therapy restored normal blood sugar levels without requiring insulin injections. The treatment reduced immune cells that attack beta cells (CD4+ and CD8+ T cells) while increasing regulatory T cells—immune cells that help calm the autoimmune response. The pancreatic tissue also showed less immune infiltration and preserved insulin secretion.

Importantly, these benefits were durable and consistent across both mouse models tested, suggesting the approach may have broad potential.

This research is early-stage, conducted only in mouse models. The use of already-approved medications is encouraging for potential translation to human research, but many therapies that work in mice do not succeed in people.

The findings add to a growing body of research exploring immune-modulation combined with strategies to restore beta-cell function. Whether this specific combination will advance to clinical trials in humans remains to be determined by further research and regulatory review.

Source: Immunotherapy advances. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.